Benzinga · Sep 8, 2026
Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back
JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.
XB
NYSE · XBI
SPDR S&P Biotech ETF
Financial Services · Asset Management
$154.18
Up+$0.15 (+0.10%)
Updated Sep 17, 2026, 3:49 AM
SID Score
5.3/10
Composite research score
Smart Money
55/100
Neutral
- Market cap
- 6.38B
- P/E ratio
- —
- Dividend yield
- 0.03%
- 52-week range
- $118.19 – $169.89
- Volume
- 8.85M
- Avg. volume
- 10.76M
Price performance
XBI price history
1M range · 20 trading sessions · Daily adjusted prices
XBI closed at $154.18 after 20 trading sessions, down 9.07% for the selected period.
- Last close
- $154.18
- Period change
- -9.07%
- Period low
- $154.03
- Period high
- $169.55
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $154.37 | $156.04 | $152.50 | $154.18 | 8.85M |
| Sep 15, 2026 | $157.08 | $157.53 | $152.63 | $154.03 | 11.3M |
| Sep 14, 2026 | $156.86 | $158.965 | $156.20 | $157.60 | 6.18M |
| Sep 11, 2026 | $158.27 | $159.6607 | $156.13 | $156.20 | 8.41M |
| Sep 10, 2026 | $157.59 | $158.72 | $155.82 | $156.82 | 9.71M |
| Sep 9, 2026 | $160.50 | $162.97 | $159.35 | $159.38 | 5.48M |
| Sep 8, 2026 | $160.765 | $163.43 | $158.795 | $161.93 | 8.52M |
| Sep 4, 2026 | $162.74 | $164.35 | $162.51 | $163.81 | 3.81M |
| Sep 3, 2026 | $165.22 | $165.96 | $162.85 | $164.38 | 5.4M |
| Sep 2, 2026 | $164.445 | $168.06 | $162.27 | $165.37 | 8.65M |
| Sep 1, 2026 | $161.75 | $163.45 | $161.16 | $163.40 | 8.45M |
| Aug 31, 2026 | $161.00 | $163.22 | $159.6206 | $162.50 | 7.36M |
| Aug 28, 2026 | $166.72 | $167.12 | $162.16 | $162.38 | 9.79M |
| Aug 27, 2026 | $167.76 | $169.27 | $166.88 | $168.23 | 4.51M |
| Aug 26, 2026 | $168.08 | $169.045 | $166.50 | $168.39 | 8.95M |
| Aug 25, 2026 | $166.18 | $169.89 | $165.79 | $169.10 | 9.9M |
| Aug 24, 2026 | $164.99 | $165.55 | $161.49 | $164.17 | 8.53M |
| Aug 21, 2026 | $164.60 | $167.9112 | $163.74 | $165.73 | 10.02M |
| Aug 20, 2026 | $166.66 | $167.53 | $162.53 | $163.38 | 15.03M |
| Aug 19, 2026 | $165.70 | $169.68 | $164.50 | $169.55 | 14.09M |
Latest XBI news
The latest Smart Investors Daily articles mentioning XBI.
Stock researchCompany · Overview
XBI research
Overview
Company profile and research snapshot.
Company profile
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
Analyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Yahoo · Sep 7, 2026
IBB Just Beat the S&P 500 by 22 Points in Three Months. Are You Late to the Party?
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the trade still have teeth, or did the easy money already leave?
SeekingAlpha · Sep 5, 2026
XBI: Big Pharma Can Keep The 76% Rally Going
Buy XBI? Get outlook for the SPDR S&P Biotech ETFâ8%â14% return target, M&A tailwinds, key risks, and volatility factors.
Yahoo · Sep 1, 2026
Healthcare ETFs to Watch Post Merck-Moderna Cancer Vaccine Breakthrough
Merck-Moderna's melanoma vaccine success could boost immunotherapy growth, putting healthcare ETFs in the spotlight.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
